A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence

Drug and Alcohol Review

Volumn 29, Issue 3, 2010, Pages 235-242

  Shearer, James ^a   Shanahan, Marian ^b   Darke, Shane ^b   Rodgers, Craig ^c   van Beek, Ingrid ^c   McKetin, Rebecca ^b   Mattick, Richard P ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SYDNEY EYE HOSPITAL   (Australia)

Author keywords

Cocaine dependence; Cost effectiveness; Methamphetamine dependence; Modafinil; Psychostimulant treatment

Indexed keywords

BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; MODAFINIL;

ADULT; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COUNSELING; DRUG ABUSE; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ADULT; AMPHETAMINE-RELATED DISORDERS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; COUNSELING; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 77957332706     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2009.00148.x     Document Type: Article

References (50)

1. Andlin-Sobocki P, Rehm J. Cost of addiction in Europe. Eur J Neurol 2005;12 (Suppl. 1):S28-33.
2. Collins D, Lapsley H. The costs of tobacco, alcohol and illicit drug abuse to Australian society in 2004/2005. National Drug Strategy Monographs No 64. 2008, Canberra: Commonwealth of Australia.
3. Rehm J, Gnam W, Popova S, et al. The costs of alcohol, illegal drugs, and tobacco in Canada, 2002. J Stud Alcohol Drugs 2007;68:886-95.
4. Office of National Drug Control Policy. The economic costs of drug abuse in the United States, 1992-2002.Washington, DC: Executive Office of the President, 2004.
5. Curtis E. Meth mouth: a review of methamphetamine abuse and its oral manifestations. Gen Dent 2006;54:125-9.
6. Saini T, Edwards PC, Kimmes NS, Carroll LR, Shaner JW, Dowd FJ. Etiology of xerostomia and dental caries among methamphetamine abusers. Oral Health Prevent Dent 2005;189-95.
7. Egred M, Davis G. Cocaine and the heart. Postgrad Med J 2005;568-71.
8. Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007;102:1204-11.
9. Gray S, Fatovich DM, McCoubrie DL, Daly FF. Amphetamine-related presentations to an inner-city tertiary emergency department: a prospective evaluation. Med J Aust 2007;186:336-9.
10. Pasic J, Russo JE, Ries RK, Roy-Byrne PP. Methamphetamine users in the psychiatric emergency services: a case control study. Am J Drug Alcohol Abuse 2007;33:675-86.
11. Kissin W, Ball J. Trends in drug-related emergency department visits, 1994-2001: at a glance. The DAWN report. Rockville: Substance Abuse and Mental Health Services Administration, 2003.
12. Chaisson R, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989;261:561-65.
13. Koblin B, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006;20:731-9.
14. Lee N, Rawson R. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008;27:309-17.
15. Roll J. Contingency management: an evidence-based component of methamphetamine use disorder treatments. Addiction 2007;102 (Suppl. 1):114-20.
16. Roozen, H, Boulogne JJ, vanTulder MW, van den Brink W, de Jong CAJ, Kerkhof AJFM. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend 2004;74:1-13.
17. Stitzer M, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther 2008;83:644-7.
18. Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. J Subst Abuse Treat 2007;41-52.
19. Shearer J, Gowing L. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 2004;23:203-11.
20. Schumacher J, Mennemeyer ST, Milby JB, Wallace D, Nolan K. Costs and effectiveness of substance abuse treatments for homeless persons. J Ment Health Policy Econ 2002;5:33-42.
21. Sindelar J, Elbel B, Petry N. What do we get for our money? Cost-effectiveness of adding contingency management. Addiction 2007;102:309-16.
22. Jofre-Bonet M, Sindelar JL, Petrakis IL, et al. Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients. J Subst AbuseTreat 2004; 16:225-32.
23. Dackis C, Kampman K, Lynch K, Pettinati H, O'Brien C. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30: 205-11.
24. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008;35:334-42.
25. Shearer J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug Alcohol Rev 2008; 301-8.
26. Shearer J, Darke S, Rodgers C, et al. A double blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009;104:224-33.
27. Baker A, Kay-Lambkin F, Lee NK, Claire M, Jenner L. A brief cognitive behavioural intervention for regular amphetamine users: a treatment guide. Canberra: Australian Government Department of Health and Ageing, 2003.
28. Del Boca F, Darkes J. Enhancing the validity and utility of randomized clinical trials in addictions research: III. Data processing and statistical analysis. Addiction 2007;102: 1356-64.
29. Brooks R, The EuroQol Group. EuroQol: the current state of play. Health Policy 1996;37:53-72.
30. Dijkgraaf M, van der Zanden BP, De Borgie CAJM, Blanken P, van Ree J, van den Brink W. Cost utility of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. Br Med J 2005;330:1297.
31. van der Zanden B, Dijkgraaf MGW, Blanken P, de Borgie CAJM, van Ree JM, Van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroindependent population. Drug Alcohol Depend 2006;82: 111-8.
32. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing... presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377-92.
33. Pharmaceutical Benefits Advisory Committee. Manual of resource items and their associated costs. Canberra: Commonwealth Department of Health and Ageing, 2002.
34. Pharmaceutical Benefits Scheme. Schedule of Pharmaceutical Benefits. 2008, Australian Government Department of Health and Ageing.
35. Australian Government Department of Health and Ageing. Medicare Benefits Schedule. 2008, Australian Government Department of Health and Ageing.
36. Australian Government Department of Health and Ageing. National Public Hospital CostWeights. 2008, Australian Government Department of Health and Ageing.
37. Australian Bureau of Statistics. Consumer price index. In: Australian Bureau of Statistics, ed. Series no. 6401 table 10. Canberra: Australian Bureau of Statistics, 2007.
38. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997;6:243-52.
39. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford University Press, 2005.
40. Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000;9:623-30.
41. Fenwick E, O'Brien B, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15.
42. Drummond M, McGuire A. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001.
43. UKATT. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). Br Med J 2005;331:541-6.
44. McKetin R, Kelly E, McLaren J, Proudfoot H. Impaired physical health among methamphetamine users in comparison with the general population: the role of methamphetamine dependence and opioid use. Drug Alcohol Rev 2008;27:482-9.
45. Shearer J, Johnston J, Fry C, et al. Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia. Drug Alcohol Rev 2007;26:537-43.
46. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
47. Poling J, Oliveto A, Petry NM, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006;63:219-28.
48. Schmitz J, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioural therapy platform. Drug Alcohol Depend 2008;94:142-50.
49. Shearer J, Shanahan M. Cost effectiveness analysis of smoking cessation intervention. Aust NZ J Public Health 2006;30:428-34.
50. Briggs A, Wonderling D, Mooney C. Pulling costeffectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.